A Stalevo-kezelés magyarországi tapasztalatai és hatása a Parkinson-kórban szenvedô betegek életminôségére.

Translated title of the contribution: The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in Parkinsonian patients with fluctuation. An observational investigation has been conducted in Hungary to study the effects of Stalevo on the "wearing off" phenomenon and on the quality of life in patients, who are to be treated with. The introduction of Stalevo to the treatment resulted in no changes in the number of patients taking selegiline, amantadine and dopamine agonists, while the number of patients taking anticholinergic drugs were slightly increased. This treatment significantly decreased the average Hoehn-Yahr stadium, as well as the non-motor symptoms, without any remarkable side effect. Stalevo also improved the quality of life, detected by the EQ-5D questionnaire and the visual analogue scale.

Original languageHungarian
Pages (from-to)42-48
Number of pages7
JournalIdeggyógyászati szemle
Volume61
Issue number1-2
Publication statusPublished - Jan 30 2008

Fingerprint

Hungary
Parkinson Disease
Quality of Life
Selegiline
Amantadine
Dopamine Agonists
Cholinergic Antagonists
Levodopa
Visual Analog Scale
Stalevo
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{685813d52738464a8b23cca0b8cd3c6e,
title = "A Stalevo-kezel{\'e}s magyarorsz{\'a}gi tapasztalatai {\'e}s hat{\'a}sa a Parkinson-k{\'o}rban szenved{\^o} betegek {\'e}letmin{\^o}s{\'e}g{\'e}re.",
abstract = "The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in Parkinsonian patients with fluctuation. An observational investigation has been conducted in Hungary to study the effects of Stalevo on the {"}wearing off{"} phenomenon and on the quality of life in patients, who are to be treated with. The introduction of Stalevo to the treatment resulted in no changes in the number of patients taking selegiline, amantadine and dopamine agonists, while the number of patients taking anticholinergic drugs were slightly increased. This treatment significantly decreased the average Hoehn-Yahr stadium, as well as the non-motor symptoms, without any remarkable side effect. Stalevo also improved the quality of life, detected by the EQ-5D questionnaire and the visual analogue scale.",
author = "P. Kliv{\'e}nyi and L. V{\'e}csei",
year = "2008",
month = "1",
day = "30",
language = "Hungarian",
volume = "61",
pages = "42--48",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "1-2",

}

TY - JOUR

T1 - A Stalevo-kezelés magyarországi tapasztalatai és hatása a Parkinson-kórban szenvedô betegek életminôségére.

AU - Klivényi, P.

AU - Vécsei, L.

PY - 2008/1/30

Y1 - 2008/1/30

N2 - The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in Parkinsonian patients with fluctuation. An observational investigation has been conducted in Hungary to study the effects of Stalevo on the "wearing off" phenomenon and on the quality of life in patients, who are to be treated with. The introduction of Stalevo to the treatment resulted in no changes in the number of patients taking selegiline, amantadine and dopamine agonists, while the number of patients taking anticholinergic drugs were slightly increased. This treatment significantly decreased the average Hoehn-Yahr stadium, as well as the non-motor symptoms, without any remarkable side effect. Stalevo also improved the quality of life, detected by the EQ-5D questionnaire and the visual analogue scale.

AB - The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in Parkinsonian patients with fluctuation. An observational investigation has been conducted in Hungary to study the effects of Stalevo on the "wearing off" phenomenon and on the quality of life in patients, who are to be treated with. The introduction of Stalevo to the treatment resulted in no changes in the number of patients taking selegiline, amantadine and dopamine agonists, while the number of patients taking anticholinergic drugs were slightly increased. This treatment significantly decreased the average Hoehn-Yahr stadium, as well as the non-motor symptoms, without any remarkable side effect. Stalevo also improved the quality of life, detected by the EQ-5D questionnaire and the visual analogue scale.

UR - http://www.scopus.com/inward/record.url?scp=43049164393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049164393&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 42

EP - 48

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 1-2

ER -